AC Immune SA (NASDAQ:ACIU) saw unusually-strong trading volume on Thursday . Approximately 791,881 shares changed hands during mid-day trading, an increase of 35% from the previous session’s volume of 588,172 shares.The stock last traded at $4.92 and had previously closed at $4.83.
Several analysts have recently weighed in on ACIU shares. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of AC Immune in a research note on Thursday, January 24th. BidaskClub raised shares of AC Immune from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. UBS Group assumed coverage on shares of AC Immune in a research report on Friday, January 4th. They set a “buy” rating and a $16.00 price objective for the company. Zacks Investment Research cut shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. Finally, ValuEngine cut shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Monday, March 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $12.35.
The firm has a market capitalization of $326.32 million, a PE ratio of -6.00 and a beta of 0.04.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in AC Immune by 7.7% during the 4th quarter. FMR LLC now owns 5,612,759 shares of the company’s stock worth $53,039,000 after buying an additional 403,086 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of AC Immune in the 4th quarter valued at $6,092,000. Citadel Advisors LLC acquired a new stake in shares of AC Immune in the 3rd quarter valued at $2,279,000. Alps Advisors Inc. acquired a new stake in shares of AC Immune in the 4th quarter valued at $1,471,000. Finally, Renaissance Technologies LLC raised its holdings in shares of AC Immune by 131.6% in the 3rd quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock valued at $418,000 after purchasing an additional 29,720 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “AC Immune (ACIU) Sees Unusually-High Trading Volume” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.wkrb13.com/2019/04/11/ac-immune-aciu-sees-unusually-high-trading-volume.html.
About AC Immune (NASDAQ:ACIU)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Story: What are the benefits of investing in REITs?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.